Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, has been making significant strides in the biotechnology sector, particularly in the development of anti-cancer drug candidates. Headquartered in Houston, Texas, Moleculin Biotech operates within the Health Care sector, focusing on innovative solutions for cancer care and skin disease treatments. As of July 6, 2026, the company’s stock is trading on the Nasdaq exchange, reflecting its ongoing efforts to advance its pharmaceutical portfolio.
The company’s journey began with its Initial Public Offering (IPO) on June 2, 2016, marking its entry into the public market. Since then, Moleculin Biotech has been dedicated to the discovery and development of novel therapeutic agents. The company’s primary focus has been on anti-cancer drugs, aiming to address unmet medical needs in oncology. This dedication is evident in their robust pipeline of drug candidates, which are currently in various stages of preclinical and clinical development.
As of the close of trading on July 1, 2026, Moleculin Biotech’s stock was priced at $2.64. This figure represents a significant recovery from its 52-week low of $1.79, recorded on March 8, 2026. The company’s stock has experienced fluctuations over the past year, reflecting the dynamic nature of the biotechnology sector and the challenges inherent in drug development. Despite these challenges, Moleculin Biotech has demonstrated resilience, with its stock reaching a 52-week high of $24 on July 17, 2025.
Moleculin Biotech’s market capitalization stands at approximately $14,087,964, underscoring its position as a growing entity within the biotechnology landscape. The company’s strategic focus on anti-cancer therapies is driven by the urgent need for more effective treatments in oncology. By leveraging cutting-edge research and development techniques, Moleculin Biotech aims to bring innovative solutions to market, potentially transforming the landscape of cancer care.
In addition to its anti-cancer initiatives, Moleculin Biotech is also exploring treatments for skin diseases. This diversification of its therapeutic portfolio highlights the company’s commitment to addressing a broad spectrum of medical conditions, thereby enhancing its potential impact on patient care.
Moleculin Biotech’s efforts are supported by a dedicated team of scientists and researchers who are at the forefront of biotechnological innovation. The company’s headquarters in Houston serves as a hub for its research activities, fostering an environment of collaboration and discovery. Through its website, www.moleculin.com , Moleculin Biotech provides stakeholders with updates on its progress, research findings, and strategic initiatives.
As Moleculin Biotech continues to navigate the complexities of drug development, its focus remains steadfast on delivering breakthrough therapies that can improve patient outcomes. The company’s journey is a testament to the potential of biotechnology to drive meaningful advancements in healthcare, offering hope to patients and families affected by cancer and other serious medical conditions.
